SciClone Pharmaceuticals, a Chinese drug developer privatized by a PE consortium at a valuation of $605 million in 2017, has relisted in Hong Kong and ended its first day of trading with a market capitalization of HK$12.7 billion ($1.64 billion).
The company sold approximately 115.9 shares at HK$18.80 apiece – the top end of the indicative range – to raise HK$2.18 billion in its IPO, according to a filing. Cornerstone investors covered nearly...
The Riverside Group has bought Australian injury management and occupational rehabilitation services provider Nabenet as part of a workplace wellbeing rollup strategy.
Dreame, a Beijing-headquartered vacuum cleaner maker backed by smart phone and consumer electronics giant Xiaomi, has raised RMB3.6 billion ($563 million) in Series C funding.
Primavera Capital Group has invested $600 million in two subsidiaries of Envision Group, a China-based manufacturer of wind turbines, smart batteries, and renewable energy management systems.
India’s Axis Bank has launched a distress buyout fund targeting INR35 billion ($468 million) via its asset management business.